Aconitum Napellus Whole Asclepias Tuberosa Floweri

證據等級: L5

預測適應症: 0 個

Aconitum Napellus Complex (Multi-Component Formula): Insufficient Data for Repurposing Prediction

One-Sentence Summary

This submission concerns a 10-component botanical/homeopathic mixture (including Aconitum napellus, Filipendula ulmaria, Pulsatilla montana, and others) with no registered indications in Taiwan and no DrugBank identifier. The TxGNN model was unable to generate repurposing predictions for this entry, most likely because multi-component complex formulas cannot be mapped to a single drug node in the knowledge graph. As a result, no clinical trial or literature evidence was retrieved, and a formal repurposing assessment cannot be completed at this stage.

Quick Overview

Item	Content
Original Indication	Not available (no Taiwan registration)
Predicted New Indication	None (TxGNN returned no predictions)
TxGNN Prediction Score	N/A
Evidence Level	Below L5 — model produced no output
US Market Status	未上市 (Not marketed)
Number of NDAs	0
Recommended Decision	Hold

Why No Prediction Was Generated

TxGNN operates on individual drug entities mapped to DrugBank IDs. This submission contains 10 distinct botanical/chemical components listed as a single drug string, none of which could be resolved to a DrugBank ID as a unified entity. As a result:

No knowledge graph node exists for this multi-component formula, preventing any graph traversal or link-prediction step.
MOA data is unavailable — the mechanism of action for the combined formula has not been characterised.
Without a resolvable drug node, neither the KG-based nor the deep-learning branch of TxGNN can score candidate disease associations.

The individual ingredients suggest a traditional use profile oriented toward pain and inflammation (e.g., Filipendula ulmaria as a source of salicylates; Aconitum napellus for neuralgia; Lithium benzoate historically for gout), but this cannot be formalised into a prediction without decomposing the formula.

Safety Considerations

Please refer to the package insert for safety information.

Note: Several individual ingredients in this formula carry well-known safety signals that warrant independent review before any clinical use:

Aconitum napellus (monkshood) is highly toxic; aconitine has a narrow therapeutic index.

Euphorbia resinifera resin (resiniferatoxin source) is a potent TRPV1 agonist.

Rhododendron tomentosum contains grayanotoxins.

A component-level safety review is strongly recommended even if regulatory data for the combined formula is absent.

Conclusion and Next Steps

Decision: Hold

Rationale: TxGNN requires a single mappable drug entity (DrugBank ID) to generate repurposing candidates; this multi-component formula could not be resolved, leaving zero predictions and zero supporting evidence.

To proceed, the following is needed:

Decompose the formula: Evaluate each of the 10 components individually through TxGNN to identify which ingredient(s) drive any therapeutic signal.
Identify the lead compound: Determine whether one active ingredient (e.g., methyl salicylate from Filipendula ulmaria, or aconitine from Aconitum napellus) is the primary pharmacological agent and re-run prediction under that entity.
Obtain a DrugBank ID: If the formula is marketed elsewhere under a single product name, locate the corresponding DrugBank or ChEMBL entry.
Component-level safety audit: Given the toxicity profile of several ingredients (especially Aconitum napellus and Euphorbia resinifera), a preclinical safety assessment is prerequisite to any repurposing attempt.
Clarify regulatory identity: Confirm whether this is a registered homeopathic preparation in any jurisdiction, which may provide indication language and safety precedent.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.